L'Oreal Critical Wavelength Criticism Based On "Flawed" Analysis - P&G
This article was originally published in The Rose Sheet
Executive Summary
L'Oreal used a "flawed technical analysis" in assessing the critical wavelength method as a UVA sunscreen testing assay, Procter & Gamble asserts in May 2 comments to FDA.
You may also be interested in...
UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey
Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light in a study conducted by Brian Diffey, Newcastle General Hospital, England, et al., and published in the December Journal of the American Academy of Dermatology.
UVA Protection Provided By 10% Of Sunscreens Tested - Researcher Diffey
Only six of 59 commercially available sunscreens met the critical wavelength standard of +/-370 nm to establish efficacy against UVA light in a study conducted by Brian Diffey, Newcastle General Hospital, England, et al., and published in the December Journal of the American Academy of Dermatology.
L'Oreal
Company developing in vitro UVA sunscreen testing method to validate in vivo Persistent Pigment Darkening assay, the company tells FDA in a recent letter reiterating its preference for the PPD method in measuring UVA protection levels. Having both validated methods "should accurately and quantitatively measure the corresponding protection benefits," L'Oreal says. The company also voices its support for separate UVA and UVB labeling; FDA is considering leaving SPF as the primary indicator of sunscreen protection (1"The Rose Sheet" Feb. 14, p. 6)